We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis, and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid Technology...